Last reviewed · How we verify

NCT02021279

ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study

Completed NA Last updated 8 February 2022
What this trial tests

NA trial testing MatriStem Pelvic Floor Matrix in Pelvic Organ Prolapse in 161 participants. Completed in 28 April 2021.

Timeline
11 June 2014
Primary endpoint
28 April 2021
28 April 2021

Quick facts

Lead sponsorIntegra LifeSciences Corporation
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment161
Start date11 June 2014
Primary completion28 April 2021
Estimated completion28 April 2021
Sites13 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Integra LifeSciences Corporation — full company profile →

Who can join

18 and older, female only, with Pelvic Organ Prolapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to assess the safety and effectiveness of MatriStem Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ prolapse. Patients are evaluated throughout a 3 year follow-up period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pelvic Organ Prolapse

Currently open trials in the same condition.

Other Integra LifeSciences Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02021279.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing